Ignite Creation Date:
2024-05-05 @ 11:38 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00099541
Status:
COMPLETED
Last Update Posted:
2009-11-23
First Post:
2004-12-15
Brief Title:
Non-small Cell Lung Cancer Registry
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A Dual-Cohort Prospective Observational Study of Unresectable Stage IIIBIV Non-Small Cell Lung Cancer Patients With and Without Bone Metastasis
Status:
COMPLETED
Status Verified Date:
2009-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial will evaluate two separate groups of patients with stage IIIBIV non-small cell lung cancer The objective of Group 1 is to investigate an FDA-approved drug in stage IIIBIV non-small cell lung cancer patients that has spread to the bones The objective of Group 2 is to see if a blood test can be used to predict when cancer-related bone lesions develop This trial is seeking patients 18 years or older that have been diagnosed with Stage IIIB or Stage IV non-small cell lung cancer that cannot be treated by surgery
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Z-NEXT | None | None | None |
| US99 | None | None | None |